Latest Conference Coverage
NeuroVoices: Lynn Bekris, PhD, on sTREM2 and GFAP to Differentiate Cognitive Status, Trajectory
September 7th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.
Role of the Cognitive Stress Test in Improving Future Alzheimer Clinical Trials: Rosie Curiel, PsyD
September 1st 2022The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve evaluation of agents in development for Alzheimer disease. [WATCH TIME: 2 minutes]
Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD
August 29th 2022Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]
Expanding on the Cognitive Stress Test and Answering Cognitive Deficit Questions: Rosie Curiel, PsyD
August 25th 2022The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]
The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhD
August 21st 2022The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]
Lessons About Alzheimer Disease and Related Dementias From GFAP, sTREM2 Astrocytes: Lynn Bekris, PhD
August 18th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed research on the use of GFAP and sTREM2 in discerning dementia with Lewy bodies from Alzheimer disease. [WATCH TIME: 4 minutes]
Raising the Awareness of Severe Preeclampsia and Recognizing Potential Long-Term Impacts
August 13th 2022Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.
Understanding the Cognitive Risks With Preeclampsia and Raising Awareness: Vesna Garovic, MD, PhD
August 11th 2022The chair of the nephrology division at Mayo Clinic discussed the major questions surrounding preeclampsia and its long-term effects, as well as whether new findings change the way clinicians treat patients with the condition. [WATCH TIME: 4 minutes]
Using the Cognitive Stress Test to Distinguish Pre-MCI and Amnestic MCI: Leeron Nahmias, BS
August 9th 2022The medical student at Nova Southeastern University provided insight on a new innovative tool called the Cognitive Stress Test that can help distinguish different cognitive states for older adults. [WATCH TIME: 6 minutes]
Using Initial Cognitive Symptoms to Predict Trajectories of Neurodegenerative Pathologies
August 6th 2022Jagan A. Pillai, MD, PhD, neurologist, Cleveland Clinic Lou Ruvo Center for Brain Health, discussed a recent study which found faster clinical progression in those with nonamnestic initial cognitive symptoms.
Severe Preeclampsia During Pregnancy Linked With Late-Life Cognitive Issues, Inflammation
August 4th 2022Inflammatory coagulation pathway activator positive extracellular vesicles were significantly increased in women with a history of severe preeclampsia compared with controls and those with milder cases.
AAIC Expert Insight: Can Alzheimer Disease Be Treated With a Single-Target Approach?
August 3rd 2022During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.
Crenezumab Fails to Meet Primary End Points in API ADAD Colombia Trial
August 2nd 2022The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.
